The University of Surrey spin-out secured early-stage backing to expand its computational fluid dynamics technology.
"The S100 Angel Investment Club and SETsquared Surrey have been instrumental in helping us take Morpheus from university research towards a commercial product. The S100 Club connected us with experienced angel investors at exactly the right stage, and the wider support from SETsquared Surrey and Surrey Research Park has helped us build the foundations of a growing business. This investment is an important step towards bringing accurate, accessible fluid simulation to market, helping companies large and small to mitigate the risks of climate change and bring new and more efficient products to market."
The funding round was led by PT1 Ventures to support product development and European expansion.
"I wanted to invest in energy tech companies shaping the future, but after three years I realised no one was building what I wanted, and I thought I’d find someone doing it. That was the genesis for me leaving,"
Gresham House Ventures led the Series B round, with participation from existing backers Pembroke VCT and Ingenii Capital.
"This round of investment means we can take what we’ve built in the UK into new European markets and compete on the global stage. Payments have been dominated by a small number of incumbents for a long time. We want to provide a powerful and efficient alternative to businesses, not just in Europe, but globally,"
The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures and will support the transition of designed drug combinations into wet-lab validation.
"Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab."
